

# MTN-017 Study-Specific Procedures Manual

---

## Table of Contents

<b>Section 1. Introduction</b>	
1.1	Sources of Procedural Information .....1-1
1.2	Procedural Information.....1-1
1.3	Investigator of Record (IoR) Responsibilities .....1-2
1.4	Study Activation Process .....1-2
<b>Section 2. Documentation Requirements</b>	
2.1	Essential Documents .....2-1
2.2	Participant Research Records .....2-2
2.2.1	Concept of Source Data and Source Documentation .....2-2
2.2.2	Required Source Documentation.....2-2
2.2.2.1	Chart Notes.....2-3
2.2.2.2	Visit Checklists.....2-4
2.2.2.3	Laboratory.....2-4
2.2.2.4	Case Report Forms (CRFs).....2-4
2.2.3	Protocol Deviations.....2-4
2.2.4	Document Organization and Participant Confidentiality.....2-5
2.3	Study Product Accountability, Chain of Custody, and Dispensing Documentation in the Pharmacy.....2-6
2.3.1	Record Retention Requirements.....2-7
2.4	Appendices .....2-8
	Section Appendix 2-1- Source Documentation of Study Procedures.....2-8
	Section Appendix 2-2 - CRFs Used as Source Documents .....2-11
	Section Appendix 2-3 - CRFs Not Used as Source Documents .....2-12
<b>Section 3. Participant Accrual and Retention</b>	
3.1	Pre-Screening Procedures .....3-1
3.2	Participant Accrual.....3-2
3.2.1	Study Accrual Plan and Site-Specific Accrual Targets .....3-2
3.2.2	In-Depth Phone Interview Accrual Targets .....3-2
3.2.3	Rectal Biopsy/Fluid Subset Accrual Targets.....3-2
3.2.4	Accrual Tips and Reminders:.....3-3
3.2.5	Participant Accrual SOP .....3-3
3.3	Participant Retention .....3-4
3.3.1	Retention Definitions.....3-4
3.3.2	Retention Requirements .....3-4
3.3.3	Retention SOPs .....3-4
3.3.4	Obtaining and Updating Locator Information .....3-5
3.3.5	Retention Tips.....3-5
3.3.6	Participants Who Voluntarily Discontinue Study Participation .....3-6
<b>Section 4. Informed Consent</b>	
4.1	Overview of Informed Consent Requirements and Procedures .....4-1
4.2	Site-Specific Informed Consent Forms .....4-2
4.3	SOP for Obtaining Informed Consent.....4-2

<b>4.4</b>	<b>Informed Consent for Screening and Enrollment</b>	<b>4-3</b>
4.4.1	Informed Consent for Specimen Storage and Possible Future Research Testing	4-3
4.4.2	Informed Consent for In-Depth Phone Interview	4-3
4.4.3	Informed Consent for Rectal Biopsy and Fluid Subset (Bangkok and Pittsburgh Sites Only)	4-3
<b>4.5</b>	<b>Informed Consent Support Materials</b>	<b>4-6</b>
4.5.1	MTN-017 Informed Consent Booklets	4-6
4.5.2	Community Fact Sheet	4-6
4.5.3	Other Informed Consent Visual Aids	4-6
<b>4.6</b>	<b>Comprehension Assessment</b>	<b>4-6</b>
4.6.1	Comprehension Assessment Tools and Scoring System	4-7
4.6.2	Administration of Comprehension Assessment	4-7
<b>4.7</b>	<b>Documenting the Informed Consent Process</b>	<b>4-8</b>
<b>4.8</b>	<b>Informed Consent Process for Participants who Resume Study Participation After Voluntary Withdrawal</b>	<b>4-9</b>
<b>4.9</b>	<b>Ongoing Assessment of Participant Comprehension</b>	<b>4-9</b>

## Section 5. Study Procedures

<b>5.1</b>	<b>Visit Considerations</b>	<b>5-1</b>
<b>5.2</b>	<b>Eligibility Determination</b>	<b>5-1</b>
<b>5.3</b>	<b>Visit Checklists</b>	<b>5-3</b>
5.3.1	Sequence of Procedures	5-3
<b>5.4</b>	<b>Screening Visit</b>	<b>5-4</b>
5.4.1	Screening and Enrollment Timeframe	5-4
5.4.2	Assignment of Participant ID Numbers	5-4
5.4.3	Screening and Enrollment Log	5-5
5.4.4	Screening Visit Procedures	5-5
5.4.5	Participants Found to be Ineligible (Screen Failures)	5-6
<b>5.5</b>	<b>Enrollment Visit</b>	<b>5-6</b>
5.5.1	Enrollment Visit Procedures	5-6
5.5.1.1	Random Assignment	5-7
5.5.1.2	Prescription Overview	5-8
5.5.1.3	Product Dispensation, Product Use Instructions, First Product Use, and Adherence Counseling	5-9
<b>5.6</b>	<b>Follow-up Visits</b>	<b>5-9</b>
5.6.1	Types of Follow-up Visits	5-9
5.6.2	Follow-up Visit Scheduling	5-9
5.6.2.1	Target Visit Dates	5-9
5.6.2.2	Visit Windows	5-10
5.6.2.3	Visits Conducted Over Multiple Days: "Split Visits"	5-10
5.6.2.4	Missed Visits	5-11
5.6.3	Follow-up Visit Procedures	5-11
5.6.3.1	Interim Visits	5-12
5.6.4	Modified Visit Procedures for Participants Who Discontinue Product Use	5-12
5.6.4.1	Participants Who Discontinue Product Use Either Voluntarily or per Investigator Discretion	5-12
5.6.4.2	Participants Who Become Infected with HIV	5-13
5.6.5	Voluntary Withdraw of Study Participation	5-14
5.6.5.1	Resumption of Study Participation After Voluntary Withdrawal	5-14

## Section 6. Counseling and Behavioral Considerations

<b>6.1</b>	<b>HIV Pre- /Post-Test Counseling</b>	<b>6-2</b>
<b>6.2</b>	<b>Risk Reduction Counseling</b>	<b>6-3</b>
<b>6.3</b>	<b>Product Use Instructions and Protocol Adherence Counseling</b>	<b>6-4</b>
6.3.1	First Dose at the Initiate Period Visit for Each Product Use Regimen	6-5

6.3.2	First Dose at the Initiate Period Visit for Participants in the Rectal Biopsy/Fluid Subset .....	6-6
6.3.3	Protocol Adherence Counseling .....	6-6
<b>6.4</b>	<b>Counseling on Collection of Rectal Biopsies for Participants in the Rectal Biopsy/Fluid Subset.....</b>	<b>6-6</b>
<b>6.5</b>	<b>Real –Time Adherence Monitoring and Counseling .....</b>	<b>6-7</b>
<b>6.6</b>	<b>Participant-Centered Product Adherence Counseling .....</b>	<b>6-7</b>
6.6.1	Visit-Specific Counseling Sessions .....	6-7
6.6.1.1	Initiate-Period Visits .....	6-7
6.6.1.2	Mid-Period Visits .....	6-8
6.6.1.3	End-Period Visits .....	6-8
<b>6.7</b>	<b>Behavioral Measures .....</b>	<b>6-8</b>
6.7.1	Web-based CASI .....	6-9
6.7.1.1	Web-based CASI Description .....	6-9
6.7.1.2	Web-based CASI Preparation.....	6-9
6.7.1.3	Web-based CASI Equipment.....	6-9
6.7.1.4	Web-based CASI Procedures.....	6-9
6.7.1.5	Web-based CASI Troubleshooting .....	6-11
6.7.2	SMS Diary.....	6-12
6.7.2.1	SMS Diary Description.....	6-12
6.7.2.2	SMS Diary Preparation .....	6-13
6.7.2.3	SMS Diary Equipment.....	6-13
6.7.2.4	SMS Diary Procedures .....	6-14
6.7.2.5	SMS Diary Troubleshooting .....	6-15
6.7.3	In-depth Interview .....	6-15
6.7.3.1	In-depth Interview Description .....	6-15
6.7.3.2	In-depth Interview Preparation.....	6-15
6.7.3.3	In-depth Interview Equipment .....	6-15
6.7.3.4	In-depth Interview Procedures.....	6-15
6.7.3.5	In-depth Interview Troubleshooting.....	6-16
6.7.4	Data Convergence Interviews.....	6-16
6.7.4.1	Data Convergence Interview Description.....	6-16
6.7.4.2	PK Data Convergence Interview .....	6-17
6.7.4.3	Data Convergence Interview Preparation .....	6-18
6.7.4.4	Post-interview Data Entry and Audio File Upload .....	6-18
6.7.4.5	Data Convergence Interview Equipment .....	6-19
6.7.4.6	Data Convergence Interview Troubleshooting.....	6-19
<b>6.8</b>	<b>Appendices .....</b>	<b>6-21</b>
	Section Appendix 1: Mock Participant ID's: .....	6-21
	Section Appendix 2: SMS Test Passwords.....	6-22

## Section 7. Study Product Considerations for Non-Pharmacy Staff

<b>7.1</b>	<b>Study Product Regimens.....</b>	<b>7-1</b>
<b>7.2</b>	<b>Study Product Use Instructions.....</b>	<b>7-2</b>
7.2.1	Truvada Tablets.....	7-2
7.2.2	Daily Tenofovir Reduced Glycerin 1% Gel.....	7-2
7.2.3	RAI-Associated Tenofovir Reduced Glycerin 1% Gel.....	7-3
7.2.4	Study Product Concerns .....	7-3
<b>7.3</b>	<b>Prescriptions and Dispensing Study Products at Initiate Period Visits.....</b>	<b>7-3</b>
<b>7.4</b>	<b>Study Product Request Slip .....</b>	<b>7-4</b>
7.4.1	Study Product Re-Supply - Dispensing Study Products at Mid-Period Visits .....	7-4
7.4.2	Product Hold/Resume.....	7-4
7.4.3	Permanent Discontinuation of Study Product .....	7-5
7.4.4	Participant-Initiated Decline of Study Product.....	7-5
7.4.5	Participant No Longer in Study .....	7-5

<b>7.5 Chain of Custody</b> .....	<b>7-5</b>
7.5.1 Dispensing from the Pharmacy Directly to Participants.....	7-5
7.5.2 Dispensing from the Pharmacy to Clinic Staff.....	7-6
<b>7.6 Unused Study Product Return and Retrieval</b> .....	<b>7-6</b>
<b>7.7 Appendices</b> .....	<b>7-8</b>
Section Appendix 7-1a: MTN-017 Prescription – Daily Oral Use.....	7-8
Section Appendix 7-1b: MTN-017 Prescription – Daily Rectal Use.....	7-9
Section Appendix 7-1c: MTN-017 Prescription – RAI-Associated Rectal Use.....	7-10
Section Appendix 7-2: MTN-017 Study Product Request Slip.....	7-11
Section Appendix 7-3a: MTN-017 Record of Receipt of Participant-Specific Study Tablets.....	7-12
Section Appendix 7-3b: MTN-017 Record of Receipt of Participant-Specific Study Gel.....	7-13
Section Appendix 7-4: MTN-017 Unused Product Returns Slip.....	7-14
Section Appendix 7-5a: MTN-017 Record of Return of Participant-Specific Study Tablets.....	7-15
Section Appendix 7-5b: MTN-017 Record of Return of Participant-Specific Study Gel.....	7-16
Section Appendix 7-6: Frequently Asked Product Use Questions.....	7-17

## Section 8. Clinical Considerations

<b>8.1 Participant-Reported Medical History (Baseline [Pre-Existing Conditions] and during Follow up)</b> .....	<b>8-2</b>
8.1.1 Pre-existing Conditions Review at Screening.....	8-2
8.1.2 Pre-existing Conditions Review at Enrollment (time of randomization).....	8-2
8.1.3 Medical History Review during Follow Up.....	8-3
<b>8.2 Participant-reported Medication History (Baseline and during Follow Up)</b> .....	<b>8-4</b>
8.2.1 Baseline Medication History.....	8-4
8.2.2 Medication History Review during Follow-Up.....	8-5
8.2.3 Prohibited Medications and Products.....	8-5
<b>8.3 Physical Exams</b> .....	<b>8-6</b>
<b>8.4 Rectal Exam</b> .....	<b>8-6</b>
8.4.1 Documentation of Rectal Exam Findings.....	8-6
8.4.2 General Technique (Preparation and Position).....	8-7
8.4.3 Visual Examination of the Perianal Area.....	8-8
8.4.4 Swab Collection for HSV Detection and HPV Typing.....	8-8
8.4.5 Digital Rectal Examination (DRE).....	8-8
<b>8.5 Specimen Collection (applicable to all study participants)</b> .....	<b>8-9</b>
8.5.1 Preparation of the Anoscope.....	8-9
8.5.2 Chlamydia trachomatis (CT)/ Neisseria gonorrhoea (GC).....	8-9
8.5.3 Rectal Sponge Collection for Adherence PK and PD.....	8-10
<b>8.6 Specimen Collection (applicable to Rectal Fluid/Tissue Subset only)</b> .....	<b>8-11</b>
8.6.1 Coagulation Testing (INR or PT).....	8-11
8.6.2 Rectal Sponge Collection for Mucosal Immunology.....	8-11
8.6.3 Enema.....	8-12
8.6.4 Rectal Tissue (biopsies) Collection.....	8-12
<b>8.7 STI/RTI/UTI Management</b> .....	<b>8-14</b>
<b>8.8 Syphilis</b> .....	<b>8-14</b>
<b>8.9 HIV Testing at Screening</b> .....	<b>8-15</b>
8.9.1 Assessment of Acute HIV Infection.....	8-15
8.9.2 HIV Testing during Follow Up.....	8-15
<b>8.10 Hepatitis B Testing</b> .....	<b>8-16</b>
<b>8.11 Hepatitis C antibody testing at Screening</b> .....	<b>8-19</b>
<b>8.12 Management of Laboratory Test Results</b> .....	<b>8-19</b>
8.12.1 Calculating Creatinine Clearance Rates (Screening Only).....	8-19
<b>8.13 Clinical and Product Use Management</b> .....	<b>8-19</b>

8.14 Pre-Exposure Prophylaxis (PrEP).....	8-19
---	------

## Section 9. Adverse Event Reporting and Safety Monitoring

9.1 Definitions.....	9-1
9.1.1 Adverse Event (AE) .....	9-1
9.1.2 Reporting AEs.....	9-2
9.2 Serious Adverse Events (SAEs) / Expedited Adverse Events (EAEs).....	9-2
9.2.1 Reporting SAEs/EAEs .....	9-3
9.2.2 Updating EAE Reports.....	9-5
9.3 Adverse Event Terminology.....	9-5
9.4 Reporting Laboratory Abnormalities as AEs.....	9-6
9.5 AEs Involving Hospitalizations/Surgical Procedures .....	9-7
9.6 Adverse Event Severity Grading.....	9-7
9.7 Adverse Event Relationship to Study Product.....	9-8
9.8 Adverse Event Outcomes and Follow-Up Information: During the Study .....	9-8
9.9 Adverse Event Outcomes and Follow-Up Information: After Study Termination .....	9-9
9.10 Reporting Recurrent Adverse Events.....	9-9
9.11 Social Harms.....	9-9
9.11.1 Addressing Reports of Social Harm.....	9-10
9.12 MTN-017 Safety Monitoring, Review, and Oversight.....	9-11
9.13 Safety Distributions from DAIDS .....	9-11
9.14 Appendices.....	9-12
Section Appendix 9-1: Resources for Safety and AE Reporting to DAIDS for the clinical research sites.....	9-12
Section Appendix 9-2: Roles and Responsibilities of the PSRT .....	9-13

## Section 10. Laboratory Considerations

10.1 Overview and General Guidance .....	10-2
10.2 Specimen Labeling.....	10-6
10.3 Procedures for Specimens that cannot be Evaluated .....	10-6
10.4 Use of LDMS .....	10-6
10.4.1 Off-Hours Contact Information .....	10-6
10.4.2 Logging in PK Samples.....	10-8
10.5 Urine Testing .....	10-8
10.5.1 Specimen Collection .....	10-8
10.5.2 Urine Chlamydia and Gonorrhea Testing .....	10-9
10.5.2.1 Instructions for transferring urine into the Gen-Probe UPT.....	10-9
10.5.2.2 Instructions for transferring urine into the GeneXpert transport reagent tube.....	10-9
10.5.3 Dipstick Urinalysis.....	10-9
10.6 Blood Testing .....	10-10
10.6.1 Specimen Collection and Initial Processing .....	10-10
10.6.2 HIV Testing .....	10-10
10.6.3 Hematology Testing .....	10-11
10.6.4 Liver and Renal Function Testing .....	10-11
10.6.5 Syphilis Testing.....	10-11
10.6.6 Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, and Hepatitis C Antibody.....	10-12
10.6.7 HSV Serology .....	10-12
10.6.8 INR/PT (Tissue Subset only) .....	10-12
10.6.9 Plasma Archive (baseline) and Plasma for Storage .....	10-12
10.6.10 Blood for Tenofovir PK.....	10-12

<b>10.7 Testing of Rectal Specimens .....</b>	<b>10-14</b>
10.7.1 Anal HSV-1/2 .....	10-14
10.7.2 Anal HPV Typing (DNA PCR).....	10-14
10.7.3 Rectal NAAT for Gonorrhea and Chlamydia.....	10-15
10.7.3.1 Instructions for collection and transport of rectal swabs for GC/CT testing with Gen-Probe: .....	10-15
10.7.3.2 Instructions for collection and transport of rectal swabs for GC/CT testing with GeneXpert: .....	10-15
10.7.4 Rectal Sponge for PK .....	10-15
10.7.5 Rectal Sponge for PD (and Mucosal Immunology* for tissue subset) .....	10-16
10.7.6 Rectal Biopsies for PD (Tissue subset only).....	10-16
10.7.7 Rectal Biopsies for PK (Tissue subset only).....	10-16
10.7.8 Rectal Biopsy for Histology (Tissue subset only).....	10-17
10.7.9 Rectal Biopsy for Proteomics (Tissue subset only).....	10-17
10.7.10 Biopsies for Mucosal T Cell Phenotyping (Tissue subset only) .....	10-17
10.7.11 Mucosal Gene Expression Array (Tissue subset only) .....	10-17
<b>10.8 Appendices .....</b>	<b>10-18</b>
Section Appendix 10-1: Procedure for preparing reagents for MTN-017 .....	10-18

## Section 11. Data Collection

<b>11.1 DataFax Overview .....</b>	<b>11-1</b>
<b>11.2 DataFax Form Completion.....</b>	<b>11-2</b>
11.2.1 General Guidelines .....	11-2
11.2.2 How to Mark Response Boxes.....	11-3
11.2.3 How to Record Numbers.....	11-4
11.2.3.1 How to Record Dates.....	11-4
11.2.3.2 How to Record Time .....	11-6
11.2.4 Data Corrections and Additions .....	11-7
11.2.5 How to Handle Missing and Unknown Data.....	11-8
11.2.6 Faxing Data Fax Forms .....	11-8
<b>11.3 Non-DataFax Forms .....</b>	<b>11-8</b>
<b>11.4 Form Storage.....</b>	<b>11-9</b>
<b>11.5 MTN Data Management SOP .....</b>	<b>11-9</b>
<b>11.6 Study-specific Data Collection.....</b>	<b>11-10</b>
11.6.1 Participant ID Numbers (PTIDs) .....	11-10
11.6.2 Study Visit Timing .....	11-10
11.6.3 Visit Codes and Page Numbers.....	11-14
11.6.4 Staff Initials/Date.....	11-16
11.6.5 Form Supply.....	11-16
11.6.6 Case Report Form Completion Schedule .....	11-16
11.6.7 Completing Interviewer-administered Forms .....	11-22
11.6.8 Site Review (Quality Control) of DataFax Forms .....	11-22
11.6.8.1 MTN-017 QC Review Step #1 .....	11-22
11.6.8.2 MTN-017 QC Review Step #2 .....	11-23
<b>11.7 Form-specific Completion Instructions.....</b>	<b>11-24</b>
<b>11.8 Case Report Forms .....</b>	<b>11-25</b>

## Section 12. Data Communiqués

## Section 13. Study Reporting Plan

<b>13.1 Purpose of Reporting Plan .....</b>	<b>13-1</b>
<b>13.2 Study Reports.....</b>	<b>13-1</b>